

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Lukas-Laskey et al.	) Group Art Unit: 1614
Application No.: 10/721,020	) Examiner: K. Weddington
Filed: November 25, 2003	) )
For: METHOD OF TREATMENT FOR DECREASING MORTALITY RESULTING FROM CONGESTIVE HEART FAILURE	Confirmation No.: 3994 )

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination in the above-referenced application.

Copies of the listed non-patent literature documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited

Application No. 10/721,020 Attorney Docket No. 04012.0385-00000

documents do not constitute "prior art" under United States law, Applicants reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should any of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: July 2, 2007

Mark J. Feldstein Reg. No. 46,693

		,	JUL 02 200	81		
IDS Form PTO/S	B/08: Substitute for for	m 1449A/PT		5 co	omplete if Known	
		No.	CO TRADEAN	Application Number	10/721,020	
INF	ORMATION D	ISCLOSU	RE	Filing Date	November 25, 2003	
	TEMENT BY			First Named Inventor	Lukas-Laskey et al.	
917	CICINICIAI DI	AFFLIOA	114 1	Art Unit	1614	
	(Use as many sheets	as necessary)		Examiner Name	K. Weddington	
Sheet	1	of	1	Attorney Docket Number	04012.0385-00000	

	U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner	Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where	
Initials	No.1	Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	,	US-				
		US-				

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
					·	

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	;  ,					
	Copy of May 16, 2007 Office Action issued in U.S. Application No. 10/721,022, 13 pages.					
		Eggertsen et al., "Acute Haemodynamic Effects of Carvedilol (BM 14190), a New Combined Beta- Adrenoceptor Blocker and Precapillary Vasodilating Agent, in Hypertensive Patients," Eur. J. Clin. Pharmacol 27:19-22 (1984).				
		Schnurr et al., "Efficiacy and Safety of Carvedilol in the Treatment of Hypertension," Journal of Cardiovascular Pharmacology, 10 (Suppl. 11):S101-S107 (1987).				
		The Merck Manual of Diagnosis and Therapy, 17 <sup>th</sup> Ed., Section 16, 1688-1692, 1999.				
		Stedman's Medical Dictionary, Houghton Mifflin Company, p. 530.				
	_					
Examiner Signature	:	Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.